NCIt definition : A recombinant bispecific antibody targeting both the immunosuppressive ligand human
programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and
the human transforming growth factor beta (TGF-beta), with potential antineoplastic
and immune checkpoint modulating activities. Upon administration, the anti-PD-L1/TGF-beta
bispecific antibody Y101D targets, binds to and neutralizes TGFbeta while simultaneously
targets, binds to, and inhibits the activity of PD-L1 on tumor cells. This prevents
both TGF-beta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases
natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores
and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible
tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers;
their overexpression is associated with increased evasion of immune surveillance and
contributes to poor prognosis.;
Semantic type(s)